Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway

Cardiovascular Research

Volumn 75, Issue 2, 2007, Pages 398-407

  Blanco Rivero, Javier ^a   Márquez Rodas, Iván ^b   Xavier, Fabiano E ^c   Aras López, Rosa ^a   Arroyo Villa, Irene ^a   Ferrer, Mercedes ^a   Balfagón, Gloria ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c DEPARTAMENTO DE MICOLOGIA   (Brazil)

Author keywords

Endothelial dysfunction; Fenofibrate; Nitric oxide; Prostaglandins

Indexed keywords

ACETYLCHOLINE; CYCLOOXYGENASE 2 INHIBITOR; FENOFIBRATE; INDOMETACIN; ISOPROSTANE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HUMAN; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOEMBOLISM; WESTERN BLOTTING;

ACETYLCHOLINE; ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENDOTHELIUM, VASCULAR; INDOMETHACIN; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITROBENZENES; PROCETOFEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS F; RATS; RATS, WISTAR; SULFONAMIDES; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 34250704851     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.03.006     Document Type: Article

References (31)

1. Mombouli J.V., and Vanhoutte P.M. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardioll 31 (1999) 61-74
2. Endemann D.H., and Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 15 (2004) 1983-1992
3. Meyers C.D., and Kashyap M.L. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 20 (2005) 307-312
4. Alvarez de Sotomayor M., Mingorance C., and Andriantsitohaina R. Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries. Atherosclerosis (2006) 10.1016/j.antherosclerosis.2006.08.041 [Electronic publication ahead of print]
5. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
6. Yang T.L., Chen M.F., Luo B.L., Yu J., Jiang J.L., and Li Y.J. Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 79-83
7. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
8. Bairaktari E.T., Tzallas C.S., Tsimihodimos V.K., Liberopoulos E.N., Miltiadous G.A., and Elisaf M.S. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 6 (1999) 113-116
9. Frost R.J., Otto C., Geiss H.C., Schwandt P., and Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87 (2001) 44-48
10. Milionis H.J., Elisaf M.S., and Mikhailidis D.P. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 9 (2003) 2425-2443
11. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
12. Diep Q.N., Amiri F., Touyz R.M., Cohn J.S., Endemann D., Neves M.F., et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 40 (2002) 866-871
13. Goya K., Sumitani S., Xu X., Kitamura T., Yamamoto H., Kurebayashi S., et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24 (2004) 658-663
14. Mollace V., Muscoli C., Masini E., Cuzzocrea S., and Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57 (2005) 217-252
15. Soria A., Gonzalez M.d.C., Vidal H., Herrera E., and Bocos C. Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats. Mol Cell Biochem 273 (2005) 97-107
16. Undas A., Celinska-Lowenhoff M., Domagala T.B., Iwaniec T., Dropinski J., Lowenhoff T., et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 94 (2005) 193-199
17. Yea P., Lib J., Sua G., and Zhang C. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. Clin Chim Acta 356 (2005) 229-232
18. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
19. Mazzone T. What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes. Nat Clin Prac Endocrinol Metab 2 (2006) 366-367
20. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22 (1993) 1-14
21. Diep Q.N., Amiri F., Touyz R.M., Cohn J.S., Endemann D., Neves M.F., et al. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36 (2004) 295-304
22. Morgan E.E., Rennison J.H., Young M.E., McElfresh T.A., Kung T.A., Tserng K.Y., et al. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 290 (2006) H1899-H1904
23. Subramanian S., Derosa M.A., Bernal-Mizrachi C., Laffely N., Cade W.T., Yarasheski K.E., et al. PPAR{alpha} activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab 291 (2006) 1365-1371
24. Blanco-Rivero J., Cachofeiro V., Lahera V., Aras-López R., Márquez-Rodas I., Salaices M., et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 46 (2005) 107-112
25. Rapoport R.M., and Williams S.P. Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 28 (1996) 64-75
26. Bos C.L., Richel D.J., Ritsema T., Peppelenbosch M.P., and Versteeg H.H. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36 (2004) 1187-1205 [23]
27. Vanhoutte P.M., Feletou M., and Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 144 (2005) 449-458
28. Escalente B., Sessa W.C., Falck J.R., Yadagiri P., and Schwartzman M. Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J Pharmacol Exp Ther 248 (1989) 229-232
29. Cracowskia J.L., Devillierb P., Durandc T., Stanke-Labesquea F., and Bessarda G. Vascular biology of the isoprostanes. J Vasc Res 38 (2001) 93-103
30. Lee H., Shi W., Tontonoz P., Wang S., Subbanagounder G., Hedrick C.C., et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87 (2000) 516-521
31. Moraes L.A., Piqueras L., and Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110 (2006) 371-385